IRIS
DE TURSI, Michele
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.030
EU - Europa 2.936
AS - Asia 2.028
SA - Sud America 261
AF - Africa 27
Continente sconosciuto - Info sul continente non disponibili 12
OC - Oceania 4
Totale 9.298
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.982
SG - Singapore 929
IE - Irlanda 672
CN - Cina 616
IT - Italia 601
SE - Svezia 422
UA - Ucraina 263
DE - Germania 237
BR - Brasile 233
FR - Francia 222
GB - Regno Unito 181
TR - Turchia 178
IN - India 131
RU - Federazione Russa 89
FI - Finlandia 74
VN - Vietnam 66
BE - Belgio 44
HK - Hong Kong 38
AT - Austria 36
CA - Canada 27
PL - Polonia 21
CZ - Repubblica Ceca 19
BD - Bangladesh 17
NL - Olanda 16
JP - Giappone 15
MX - Messico 14
EU - Europa 11
EG - Egitto 8
IQ - Iraq 8
ES - Italia 7
AR - Argentina 6
LT - Lituania 6
RO - Romania 6
GR - Grecia 5
MA - Marocco 5
PK - Pakistan 5
PT - Portogallo 5
UZ - Uzbekistan 5
CO - Colombia 4
UY - Uruguay 4
ZA - Sudafrica 4
AU - Australia 3
JO - Giordania 3
KE - Kenya 3
PE - Perù 3
PY - Paraguay 3
VE - Venezuela 3
AE - Emirati Arabi Uniti 2
CL - Cile 2
EC - Ecuador 2
ET - Etiopia 2
ID - Indonesia 2
IL - Israele 2
JM - Giamaica 2
TW - Taiwan 2
AL - Albania 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BG - Bulgaria 1
BH - Bahrain 1
BO - Bolivia 1
BY - Bielorussia 1
CH - Svizzera 1
CI - Costa d'Avorio 1
DK - Danimarca 1
DZ - Algeria 1
GT - Guatemala 1
IR - Iran 1
KR - Corea 1
LB - Libano 1
LV - Lettonia 1
LY - Libia 1
MM - Myanmar 1
MT - Malta 1
NG - Nigeria 1
NI - Nicaragua 1
NO - Norvegia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PH - Filippine 1
PR - Porto Rico 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 9.298
Salva come PNG Salva come JPEG
Città #
Chandler 877
Singapore 655
Dublin 648
Jacksonville 446
Princeton 262
Ashburn 196
Beijing 169
The Dalles 130
Nanjing 124
Chieti 116
Izmir 112
Dearborn 105
Wilmington 105
Southend 104
Santa Clara 103
Altamura 100
Ann Arbor 89
Munich 74
Pescara 71
Los Angeles 70
Boardman 57
New York 55
Cambridge 54
Dong Ket 47
Brussels 43
Washington 39
Hong Kong 38
Menlo Park 36
Tongling 32
Nanchang 30
Shenyang 24
Nuremberg 23
Rome 23
Council Bluffs 21
Helsinki 21
Norwalk 21
Frankfurt am Main 20
Hefei 20
Boston 19
Falls Church 19
Hebei 19
São Paulo 19
Vienna 19
Woodbridge 19
Kunming 18
Houston 17
Seattle 16
Tianjin 16
Milan 15
Amsterdam 13
Ancona 13
Jiaxing 13
Tokyo 13
Turku 13
Hangzhou 12
Ho Chi Minh City 12
Hyderabad 12
Brno 11
Chicago 11
London 11
Brooklyn 10
Edinburgh 10
Warsaw 10
Phoenix 9
Pune 9
Redwood City 9
Cairo 8
Grevenbroich 8
Kraków 8
Montreal 8
San Francisco 8
Campinas 7
Changchun 7
Dallas 7
Dhaka 7
Shanghai 7
Atlanta 6
Belo Horizonte 6
Changsha 6
Charlotte 6
Guangzhou 6
Mcallen 6
Mexico City 6
Rio de Janeiro 6
Toronto 6
Ascoli Piceno 5
Columbus 5
Franca 5
Giaveno 5
Lanciano 5
Moscow 5
Pisa 5
Shijiazhuang 5
Simi Valley 5
Tappahannock 5
Brasília 4
Curitiba 4
L’Aquila 4
Madrid 4
Miami 4
Totale 5.746
Salva come PNG Salva come JPEG
Nome #
Breast cancer "tailored follow-up" in Italian oncology units: A web-based survey 132
PERITONECTOMIA ED HIPEC NEL TRATTAMENTO DELLA CARCINOSI PERITONEALE: RISULTATI PRELIMINARI DOPO UN ANNO DI ESPERIENZA 127
A multicenter phase II study of Epirubicin (E) with low-dose Herceptin (LD-H) as a first line treatment in HER-2 overexpressing metastatic breast cancer (MBC): Preliminary Results 123
The 90K protein increases major histocompatibility complex class I expression and is regulated by hormones, gamma-interferon, and double-strand polynucleotides. 123
New Targets for Therapy in Pancreatic Cancer 123
Impact of BMI on clinical outcome in advanced cancer patients treated with anti‑PD‑1 Immune checkpoint inhibitors: a preliminary analysis 122
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer. 120
Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation 114
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting 109
Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells 109
Optimizing Single Agent Panitumumab Therapy in Pre-Treated Advanced Colorectal Cancer 108
PO-1074 Radiotherapy and immuno-check point inhibitors for brain metastases. A mono-institutional analysis 106
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer 105
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable 104
Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice. 103
Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials 103
An Epigenetic Approach to Pancreatic Cancer Treatment: the Prospective Role of Histone Deacetylase Inhibitors 102
A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression 101
Extraordinary and prolonged erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: A case report 100
Abiraterone Acetate for Treatment of Metastatic Castration-resistant Prostate Cancer in Chemotherapy-naive Patients: An Italian Analysis of Patients' Satisfaction 100
Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients 100
ABIRATERONE ACETATE FOR TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN CHEMOTHERAPY-NAIVE PATIENTS: AN ITALIAN MULTICENTER 'REAL-LIFE' 1-YEAR STUDY 100
Principali effetti collaterali delle terapie mediche 97
Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis 95
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 95
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study 94
Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study 94
Cytokine Levels and UVr Sensitivity in HaCaT Cells and Cetuximab Treated Patients. 93
Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter "real life" study 93
Arterial Thrombosis in ambulatory cancer patients treated with chemotherapy. 93
High Blood Concentration of Leukocyte-Derived Extracellular Vesicles Is Predictive of Favorable Clinical Outcomes in Patients with Pancreatic Cancer: Results from a Multicenter Prospective Study 92
Relief of symptoms after gefitinib is associated with improvement of rest/activity rhythm in advanced lung cancer 91
Speed rate (SR) as a new dynamic index of melanoma behavior 91
null 90
Blood Circulating CD133+ Extracellular Vesicles Predict Clinical Outcomes in Patients with Metastatic Colorectal Cancer 89
A multicenter phase II study of Epirubicin with low-dose Herceptin as a first line treatment in HER-2 overexpressing metastatic breast cancer 89
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study 89
Persistence and adherence to androgen deprivation therapy in men with prostate cancer: an administrative database study 89
Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study 88
Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of EGFR mutations in NSCLC: A new algorithm for patient selection and personalized treatment 88
Chronomodulated infusion of cisplatin, 5-fluorouracil and folinic acid: lack of activity in advanced colorectal cancer. 87
The use of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy(HIPEC) in patients undergoing cytoreductive surgery (CS) for peritoneal carcinomatosis ofovarian origin 87
Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of NSCLC patients 86
A real-life multicenter, retrospective analysis of Abiraterone Acetate (AA) in 340 metastatic castration-resistant prostate cancer (mCRPC) patients after chemotherapy, updated results 83
Effect of targeted agents on the endocrine response of breast cancer in the neoadjuvant setting: A systematic review 82
Rivaroxaban for cancer-associated cardiac thrombosis 82
Relationship and predictive role of the dual expression of FGFR and IL8 in metastatic renal cell carcinoma (mRCC) 82
Asymptomatic venous thromboembolism in patients with solid tumors treated with chemotherapy: An underestimated phenomenon 81
Skin toxicity evaluation in patients treated with cetuximab for metastatic colorectal cancer: a new tool for more accurate comprehension of quality of life impacts 80
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 80
Enzalutamide in patients with castration-refractory prostate cancer: Retrospective, multicenter, real life study 80
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 80
Real world treatment practice in patients with advanced melanoma in the nivolumab era: five novel Italian case reports and a literature review 79
Corrigendum to "Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation" 79
Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy 78
Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study 77
INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study 77
A real -life multicenter study on body weight loss and body mass index in advanced Gastric Cancer patients treated with Ramucirumab-based second -line therapy 77
Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial 76
Multicentric retrospective analysis of platinum-pemetrexed regimens as first-line therapy in non-squamous non-small cell lung cancer patients: A “snapshot” from clinical practice 75
Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: A dose-finding study 74
Peritonectomy and hyperthermic chemotherapy in patients with advanced or recurrent ephitelial ovarian cancer: a single center cohort study 74
Quantification of EGFR Mutations in Plasma of NSCLC Patients: An Early Predictor of Clinical Response to Tyrosine Kinase Inhibitor 73
Cabazitaxel after Docetaxel in patients with metastatic, castration-resistant, prostate cancer (mCRPC): A prospective, observational study about toxicity profile and quality of life. 72
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status 72
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes 72
Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The PRACTICE study 72
Alectinib induced regression of renal and hepatic cysts caused by crizotinib 72
Epirubicin plus low-dose trastuzumab in HER2 positivemetastatic breast cancer 71
Asymptomatic venous thromboembolism in patients with solid tumors treated with chemotherapy: An underestimated phenomenon 71
F05Relationship and predictive role of the dual expression of FGFR and IL8 in metastatic renal cell carcinoma (mRCC) 71
Relationship and predictive role of the dual expression of FGFR and IL8 in metastatic renal cell carcinoma (mRCC) 71
Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: A retrospective multicenter study 71
Relationship and predictive role of the dual expression of FGFR and IL-8 in metastatic renal cell carcinoma treated with targeted agents 70
Enzalutamide in real life: Results from a retrospective, multicenter, italian study 70
Tgf-β1 transcriptionally promotes 90K expression: possible implications for cancer progression 70
Enzalutamide in patients with castration-resistant prostate cancer: retrospective, multicenter, real life study 69
Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score 69
Phenotypic and proteomic analysis identifies hallmarks of blood circulating extracellular vesicles in NSCLC responders to immune checkpoint inhibitors 69
Outcomes of systemic therapy in relapsed renal cell carcinoma (RCC) treated with adjuvant sunitinib (AS) 67
Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study. 66
Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer 65
null 65
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study 65
Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study 64
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events 64
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50 64
Increased tolerability of bimonthly 12-hour timed flat infusion 5-fluorouracil/irinotecan regimen in advanced colorectal cancer: A dose-finding study. 63
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients 63
Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results 62
Nivolumab and diabetes mellitus: safe administration in a patient with pancreatic metastases from melanoma 61
Treatment and outcome (s) of a large cohort of Italian patients (pts) with poor-risk metastatic renal cell carcinoma (prRCC) 60
PO-06 Asymptomatic venous thromboembolism in patients with solid tumors treated with chemotherapy: An underestimated phenomenon 60
Long-term performance of risk scores for venous thromboembolism in ambulatory cancer patients 60
Evaluation of second-line anti-VEGF after first-line anti-EGFR based therapy in RAS wild-type metastatic colorectal cancer: The multicenter “SLAVE” study 59
Nivolumab in Advanced Non-Squamous NSCLC Patients with KRAS Mutations: Results from the Italian Expanded Access Program (EAP) 58
A multicenter phase II study of epirubicin (E) with low-dose herceptin (LD-H) as a first-line treatment in HER2 overexpressing metastatic breast cancer (MBC) 58
Breast cancer follow-up strategies in randomized phase III adjuvant clinical trials: a systematic review 57
High blood concentration of circulating cancer stem cell-derived extracellular vesicles is associated with poor survival in advanced colorectal cancer patients 57
Epidermal Growth Factor Immunotherapy: Exploring the Effects of NB-UVB Exposure 56
Totale 8.339
Salva come PNG Salva come JPEG
Categoria #
all - tutte 46.712
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 46.712
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021693 0 28 153 21 51 168 33 24 58 51 30 76
2021/2022803 19 28 14 193 75 26 20 43 51 20 68 246
2022/20232.328 205 323 188 257 166 411 115 216 273 23 103 48
2023/20241.042 63 32 79 34 67 394 177 43 25 35 10 83
2024/20252.335 133 454 303 68 56 125 120 126 256 140 290 264
2025/2026487 409 78 0 0 0 0 0 0 0 0 0 0
Totale 10.042